Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 11/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.74 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.71 |
| ▸ | AURKA | O14965 | 1/20 | 0.71 |
| ▸ | FLT3 | P36888 | 1/20 | 0.65 |
| ▸ | EGFR | P00533 | 5/20 | 0.64 |
| ▸ | JAK2 | O60674 | 1/20 | 0.62 |
| ▸ | IGF1R | P08069 | 1/20 | 0.62 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13641247 | 0.91 | AXL (0.84) | AXLALKAURKBAURKAFLT3 | |
| SCHEMBL12964736 | 0.88 | AXL (0.79) | AXLALKAURKBAURKAFLT3 | |
| SCHEMBL12964728 | 0.87 | AXL (1.00) | AXLALKAURKBAURKAEGFR | |
| SCHEMBL12964725 | 0.86 | AXL (1.00) | AXLALKAURKBAURKAEGFR | |
| SCHEMBL22872058 | 0.83 | AXL (0.71) | AXLALKAURKBAURKAJAK2 | |
| Dubermatinib SCHEMBL12813478 | 0.83 | AXL (1.00) | AXLALKAURKBAURKAJAK2 | |
| Dubermatinib SCHEMBL29394359 | 0.83 | AXL (1.00) | AXLALKAURKBAURKAJAK2 | |
| SCHEMBL24073135 | 0.82 | AXL (0.70) | AXLALKAURKBAURKAJAK2 | |
| SCHEMBL28586392 | 0.82 | EGFR (0.73) | AXLAURKBAURKAEGFRIGF1R | |
| SCHEMBL25837702 | 0.82 | AXL (0.80) | AXLALKAURKBAURKAJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165857-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | SUMITOMO PHARMA ONCOLOGY, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20210205304-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-07-08 | — | — | US | disclosed |
| EP-3628665-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | University of Utah Research Foundation (US) | 2020-04-01 | — | — | EP | disclosed |
| WO-2019195753-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | TOLERO PHARMACEUTICALS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| EP-2693881-B1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | UNIV UTAH RES FOUND (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-2693881-B1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | UNIV UTAH RES FOUND (US) | 2019-09-04 | — | — | EP | disclosed |
| US-8901120-B2 | Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinase | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901120-B2 | Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinase | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901120-B2 | Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinase | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-12-02 | — | — | US | disclosed |
| EP-2693881-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | University of Utah Research Foundation (US) | 2014-02-12 | — | — | EP | disclosed |
| US-20120283261-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | SUMITOMO PHARMA ONCOLOGY, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20120283261-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | SUMITOMO PHARMA ONCOLOGY, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20120283261-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | SUMITOMO PHARMA ONCOLOGY, INC. | 2012-11-08 | — | — | US | disclosed |
| WO-2012135800-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012135800-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283261-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | AXL, TYRO3, MERTK | AXL 1/4885ALK 112/4885AURKB 198/4885 |
| US-20210205304-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | AXL, FLT3, TEC | AXL 1/4885ALK 17/4885AURKB 146/4885 |
| US-20230165857-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | AXL, FLT3, TEC | AXL 1/4885ALK 23/4885AURKB 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.